François-Xavier Mahon, MD, PhD, on Chronic-Phase Chronic Myeloid Leukemia: Treatment-Free Remission After Second-Line Treatment
2019 ASCO Annual MeetingFrançois-Xavier Mahon, MD, PhD, of the Université Bordeaux and Institut Bergonie, discusses results of the ENESTop study, which demonstrated the long-term durability and safety of treatment-free remission in chronic-phase CML after second-line nilotinib (Abstract 7005).
Related Videos
Richard T. Penson, MD, and Don S. Dizon, MD, on Ovarian Cancer: SOLO3 Trial on Olaparib vs Chemotherapy in Relapsed Disease
Don S. Dizon, MD, of the Lifespan Cancer Institute, and Richard T. Penson, MD, of Massachusetts General Hospital Cancer Center, discuss phase III study findings on...
Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Breast Cancer: Next Steps in Immunotherapy
Hope S. Rugo, MD, of the University of California, San Francisco, and Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, discuss on...
Hirotsugu Kenmotsu, MD, on Nonsquamous Non–Small Cell Lung Cancer: Pemetrexed Plus Cisplatin vs Vinorelbine Plus Cisplatin
Hirotsugu Kenmotsu, MD, of Shizuoka Cancer Center, discusses the phase III JIPANG trial findings, which showed that pemetrexed plus cisplatin was not superior to vinorelbine plus c...
Angela Lamarca, MD, PhD, on Biliary Tract Cancers: Active Symptom Control With Oxaliplatin and Fluorouracil
Angela Lamarca, MD, PhD, of The Christie NHS Foundation Trust and the University of Manchester, discusses phase III findings from a multicenter study of active symptom contro...
Danny Rischin, MD, on Head and Neck Squamous Cell Carcinoma: KEYNOTE-048 Trial on Pembrolizumab
Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase III results that support pembrolizumab with and without platinum-based chemotherapy plus fluorouracil as ...
